News | October 29, 2021
Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Gini Health works in the domain of personalised healthcare
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Acute therapies continue to report strong growth compared to chronic ones.
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It answers the most basic questions from a patient’s perspective
Filing marks first protein-based vaccine submitted to MHRA for authorization
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
